Lifeboat Foundation: Safeguarding Humanity
Toggle light / dark theme

Blog

Category: health – Page 237

Despite high vaccine coverage and effectiveness, the incidence of symptomatic infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has been increasing in Israel. Whether the increasing incidence of infection is due to waning immunity after the receipt of two doses of the BNT162b2 vaccine is unclear.

As the rollout of vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)1,2 is expanding worldwide, data on the durability of protection are limited. A randomized, controlled trial and real-world studies have shown vaccine efficacy of 94 to 95% with the BNT162b2 vaccine (Pfizer–BioNTech) and vaccine effectiveness in preventing symptomatic coronavirus disease 2019 (Covid-19) 7 days or more after receipt of the second dose of vaccine.1,3–5 Real-world effectiveness and immunogenicity data describing the antibody kinetics over time after vaccination are beginning to appear, but a complete picture of the duration of immunity is not yet available. We recently reported that breakthrough infection in BNT162b2-vaccinated persons was correlated with neutralizing antibody titers.6 However, a threshold titer that can predict breakthrough infection has not been defined.

The BNT162b2 vaccine elicits high IgG and neutralizing antibody responses 7 to 14 days after receipt of the second dose. Lower antibody levels have been shown to develop in older persons, men, and persons with an immunosuppressed condition, which suggests that antibody titers in these populations may decrease earlier than in other populations.7,8 A decrease in anti-spike (S) antibody levels by a factor of two was observed from the peak (at 21 to 40 days) to 84 days after receipt of the second dose of the BNT162b2 vaccine among 197 vaccinated persons.9 Here, we report the results of a large-scale, real-world, longitudinal study involving health care workers that was conducted to assess the kinetics of immune response among persons with different demographic characteristics and coexisting conditions throughout the 6-month period after receipt of the second dose of the BNT162b2 vaccine.

Read more | >

A FIVE-DAY COURSE of molnupiravir, the new medicine being hailed as a “huge advance” in the treatment of Covid-19, costs $17.74 to produce, according to a report (pdf) issued last week by drug pricing experts at the Harvard School of Public Health and King’s College Hospital in London. Merck is charging the U.S. government $712 for the same amount of medicine, or 40 times the price. (taxpayer funded mind you)

The Covid-19 treatment molnupiravir was developed using funding from the National Institutes of Health and the Department of Defense.

Read more | >

It probably didn’t feel like much, but that simple kind of motion required the concerted effort of millions of different neurons in several regions of your brain, followed by signals sent at 200 mph from your brain to your spinal cord and then to the muscles that contracted to move your arm.

At the cellular level, that quick motion is a highly complicated process and, like most things that involve the human brain, scientists don’t fully understand how it all comes together.

Now, for the first time, the neurons and other cells involved in a region of the human, mouse and monkey brains that controls movement have been mapped in exquisite detail. Its creators, a large consortium of neuroscientists brought together by the National Institutes of Health’s Brain Research Through Advancing Innovative Neurotechnologies® (BRAIN) Initiative, say this brain atlas will pave the way for mapping the entire mammalian brain as well as better understanding mysterious brain diseases — including those that attack the neurons that control movement, like amyotrophic lateral sclerosis, or ALS.

Read more | >

There’s a lot of excitement at the intersection of artificial intelligence and health care. AI has already been used to improve disease treatment and detection, discover promising new drugs, identify links between genes and diseases, and more.

By analyzing large datasets and finding patterns, virtually any new algorithm has the potential to help patients — AI researchers just need access to the right data to train and test those algorithms. Hospitals, understandably, are hesitant to share sensitive patient information with research teams. When they do share data, it’s difficult to verify that researchers are only using the data they need and deleting it after they’re done.

Secure AI Labs (SAIL) is addressing those problems with a technology that lets AI algorithms run on encrypted datasets that never leave the data owner’s system. Health care organizations can control how their datasets are used, while researchers can protect the confidentiality of their models and search queries. Neither party needs to see the data or the model to collaborate.

Read more | >

With almost instant improvement.

A team of researchers from the University of California, San Francisco Health has successfully treated a patient with severe depression by targeting the specific brain circuit involved in depressive brain patterns and resetting them thanks to a new proof-of-concept intervention.

Even though it centers around one patient, the groundbreaking study, which has now been published in Nature Medicine, is an important step toward bringing neuroscience advances and the treatment of psychiatric disorders, potentially helping millions of people who suffer from depression.

Read more | >

Based on Transformers, our new architecture advances genetic research by improving the ability to predict how DNA sequence influences gene expression.

When the Human Genome Project succeeded in mapping the DNA sequence of the human genome, the international research community were excited by the opportunity to better understand the genetic instructions that influence human health and development. DNA carries the genetic information that determines everything from eye colour to susceptibility to certain diseases and disorders. The roughly 20,000 sections of DNA in the human body known as genes contain instructions about the amino acid sequence of proteins, which perform numerous essential functions in our cells. Yet these genes make up less than 2% of the genome. The remaining base pairs — which account for 98% of the 3 billion “letters” in the genome — are called “non-coding” and contain less well-understood instructions about when and where genes should be produced or expressed in the human body.

Read more | >

Human Factors, Ethical Artificial Intelligence, And Healthy Aging — Dr. Arathi Sethumadhavan, PhD, Head of User Research, AI, Ethics & Society, Microsoft Cloud+AI.

Dr. Arathi Sethumadhavan, Ph.D. is Head of User Research for AI, Ethics & Society, at Microsoft’s Cloud+AI organization, where she works at the intersection of user research, ethics, and product experience.

In her current role, Dr. Sethumadhavan is focused on the Microsoft AI ethical principles (privacy and consent, fairness, inclusion, accountability, and transparency) as it relates to various Microsoft AI experiences.

Dr. Sethumadhavan is a seasoned research leader, with two decades of experience studying human-technology interaction, and during the course of her career, she has led user research for several novel and complex applications (e.g., Microsoft’s custom neural voice, facial recognition), as well as at Medtronic, where she provided human factors leadership to multiple products in the Cardiac Rhythm and Heart Failure portfolio, including the world’s smallest pacemaker. She has also spent several years investigating the implications of automation on air traffic controller performance and situation awareness.

Dr. Sethumadhavan is also a Fellow at the World Economic Forum, where she is working on unlocking opportunities for positive impact with AI to address the needs of the aging population.

Continue reading “Dr. Arathi Sethumadhavan, PhD — Head of User Research, AI, Ethics & Society, Microsoft’s Cloud+AI” | >

“In the preliminary data … there is a suspicion of an increased risk of heart inflammation, when vaccinated with Moderna,” the Danish Health Authority said in a statement.

It referred to data from a yet unpublished Nordic study, which would now be sent to the European Medicines Agency (EMA) for further assessment. Final data was expected within a month, it added.

Sweden and Denmark said they now recommended the Comirnaty vaccine, from Pfizer/BioNTech (PFE.N), 0 instead.

Read more | >

Microsoft has confirmed that its financial services-focused industry cloud will be officially available on November 1 2021.

The news comes eight months after the company revealed it was launching three new industry clouds this year — for manufacturing, not-for-profits, and financial services. Today’s announcement means the financial-focused cloud is the first of the three to receive an official launch date, though Microsoft has previously introduced an industry cloud for health care and its retail-focused incarnation currently sits in public preview.

Full Story:

Read more | >